Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer

Journal of Urology

Volumn 196, Issue 4, 2016, Pages 1261-1267

  Rhee, H ^a,d   Thomas, P ^b   Shepherd, B ^a   Gustafson, S ^a   Vela, I ^a,d   Russell, P J ^d   Nelson, C ^d   Chung, E ^a   Wood, G ^c   Malone, G ^a,c   Wood, S ^a,c   Heathcote, P ^a,c,d  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c GREENSLOPES PRIVATE HOSPITAL   (Australia)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

magnetic resonance imaging; pathology; positron emission tomography; prostate

Indexed keywords

GALLIUM 68; GALLIUM HBED CC GA 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG UPTAKE; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET-CT SCANNER; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; PROSTATE; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 84992695908     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2016.02.3000     Document Type: Article

References (25)

1. 1 Heijnsdijk, E.A., Wever, E.M., Auvinen, A., et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med, 367, 2012, 595.
2. 2 Pokorny, M.R., de Rooij, M., Duncan, E., et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol, 66, 2014, 22.
3. 3 Ahmed, H.U., Kirkham, A., Arya, M., et al. Is it time to consider a role for MRI before prostate biopsy?. Nat Rev Clin Oncol, 6, 2009, 197.
4. 4 Le, J.D., Tan, N., Shkolyar, E., et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol, 67, 2015, 569.
5. 5 National Institute for Health and Care Excellence: Prostate cancer: diagnosis and management. Clinical guideline 175 (Update of clinical guideline 58). Available at http://www.nice.org.uk/guidance/cg175/evidence/cg175-prostate-cancer-full-guideline3.
6. 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med, 56, 2015, 668.
7. 7 Ceci, F., Uprimny, C., Nilica, B., et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. Eur J Nucl Med Mol Imaging, 42, 2015, 1284.
8. 8 Budaus, L., Leyh-Bannurah, S.R., Salomon, G., et al. Initial experience of Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol, 69, 2016, 393.
9. 9 Kayat Bittencourt, L., Litjens, G., Hulsbergen-van de Kaa, C.A., et al. Prostate cancer: the European Society of Urogenital Radiology Prostate Imaging Reporting and Data System Criteria for predicting extraprostatic extension by using 3-T multiparametric MR imaging. Radiology, 276, 2015, 479.
10. 10 Eder, M., Löhr, T., Bauder-Wüst, U., et al. Pharmacokinetic properties of peptidic radiopharmaceuticals: reduced uptake of (EH)3-conjugates in important organs. J Nucl Med, 54, 2013, 1327.
11. 11 Afshar-Oromieh, A., Haberkorn, U., Hadaschik, B., et al. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging, 40, 2013, 1629.
12. 12 Ahmed, H.U., Hu, Y., Carter, T., et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol, 186, 2011, 458.
13. 13 Mitra, J., Kato, Z., Marti, R., et al. A spline-based non-linear diffeomorphism for multimodal prostate registration. Med Image Anal, 16, 2012, 1259.
14. 14 Bratan, F., Melodelima, C., Souchon, R., et al. How accurate is multiparametric MR imaging in evaluation of prostate cancer volume?. Radiology, 275, 2015, 144.
15. 15 van den Bos, W., Muller, B.G., Ahmed, H., et al. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol, 65, 2014, 1078.
16. 16 Marshall, S., Taneja, S., Focal therapy for prostate cancer: the current status. Prostate Int, 3, 2015, 35.
17. 17 Liu, W., Laitinen, S., Khan, S., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med, 15, 2009, 559.
18. 18 Haffner, M.C., Mosbruger, T., Esopi, D.M., et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest, 123, 2013, 4918.
19. 19 Lohr, J.G., Adalsteinsson, V.A., Cibulskis, K., et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol, 32, 2014, 479.
20. 20 Barbieri, C.E., Demichelis, F., Rubin, M.A., The lethal clone in prostate cancer: redefining the index. Eur Urol, 66, 2014, 395.
21. 21 Klein, E.A., Cooperberg, M.R., Magi-Galluzzi, C., et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol, 66, 2014, 550.
22. 22 Wright, G.L. Jr., Grob, B.M., Haley, C., et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 48, 1996, 326.
23. 23 Grauer, L.S., Lawler, K.D., Marignac, J.L., et al. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res, 58, 1998, 4787.
24. 24 Schwarzenbock, S., Souvatzoglou, M., Krause, B.J., Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics, 2, 2012, 318.
25. 25 Afshar-Oromieh, A., Avtzi, E., Giesel, F.L., et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging, 42, 2015, 197.